X4 Pharmaceuticals Inc (XFOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) has a cash flow conversion efficiency ratio of -0.452x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.82 Million) by net assets ($61.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
X4 Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how X4 Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read X4 Pharmaceuticals Inc (XFOR) total liabilities for a breakdown of total debt and financial obligations.
X4 Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of X4 Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DSC Investment Inc
KQ:241520
|
-0.040x |
|
Kelly Services A Inc
NASDAQ:KELYA
|
0.029x |
|
Canaan Inc
NASDAQ:CAN
|
-0.497x |
|
D. Boral ARC Acquisition I Corp. Class A Ordinary Shares
NASDAQ:BCAR
|
N/A |
|
Ace Pillar Co Ltd
TW:8374
|
-0.014x |
|
Argo Global Listed Infrastructure Ltd
AU:ALI
|
0.025x |
|
Tus-Design Group Co Ltd Class A
SHE:300500
|
0.075x |
|
RMR Group Inc
NASDAQ:RMR
|
0.026x |
Annual Cash Flow Conversion Efficiency for X4 Pharmaceuticals Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of X4 Pharmaceuticals Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see XFOR market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $22.15 Million | $-130.90 Million | -5.910x | -212.91% |
| 2023-12-31 | $51.10 Million | $-96.51 Million | -1.889x | -81.40% |
| 2022-12-31 | $74.05 Million | $-77.10 Million | -1.041x | +5.41% |
| 2021-12-31 | $64.41 Million | $-70.91 Million | -1.101x | -36.25% |
| 2020-12-31 | $72.80 Million | $-58.82 Million | -0.808x | -117.26% |
| 2019-12-31 | $129.22 Million | $-48.05 Million | -0.372x | +80.36% |
| 2018-12-31 | $21.60 Million | $-40.90 Million | -1.894x | -298.88% |
| 2017-12-31 | $58.71 Million | $-27.87 Million | -0.475x | -224.09% |
| 2016-12-31 | $-56.56 Million | $-21.64 Million | 0.383x | +21.40% |
| 2015-12-31 | $-34.32 Million | $-10.82 Million | 0.315x | -- |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, an… Read more